01—Abstract
Summary
Summary of the 8-K filed April 30, 2026. Cited figures are marked; the original filing is the authoritative source.
ResMed Inc. announced on April 30, 2026 that Chief Financial Officer Brett Sandercock will retire from his roles as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.
He will remain CFO until May 4, 2026, then serve as Special Advisor to Chairman and CEO Mick Farrell through December 31, 2026, and continue in a consulting role from January 1, 2027 through December 31, 2027. The filing states his retirement did not result from any disagreement with the Company on operations, policies, or practices. He will keep his current salary, benefits and long-term equity vesting, and remain eligible for a six-month, pro-rata payment of his fiscal year 2027 short-term incentive.
Aaron Bloomer, age 40, was appointed Chief Financial Officer effective May 4, 2026, serving as Principal Financial Officer and Principal Accounting Officer. He most recently was Executive Vice President and CFO of Exact Sciences Corporation and previously held senior finance roles at Baxter International and 3M.
His compensation includes an annual base salary of $725,000,a a $150,000 sign-on bonus subject to repayment if he leaves voluntarily within 24 months, an annual short-term incentive target of 80% of base salary (pro-rated for fiscal year 2026), a long-term performance equity grant of $3,300,000 on joining, relocation assistance to San Diego, and an additional $3,300,000 equity grant eligible in November 2026 for fiscal year 2027, subject to committee approval. The press release (Exhibit 99.1) states that ResMed reported third quarter fiscal year 2026 results the same day and reiterated its fiscal year 2026 outlook, including gross margin of 62-63%, SG&A expenses of 19-20%, R&D expenses of 6-7%, and an effective tax rate of 21-23%.
02—Key points
Key Highlights
- CFO transition: Brett Sandercock retires as CFO effective May 4, 2026, then becomes Special Advisor to the Chairman and CEO through December 31, 2026, with a consulting role in 2027.
- Successor named: Aaron Bloomer, age 40, joins as CFO effective May 4, 2026, as PFO and PAO, most recently from Exact Sciences, with prior roles at Baxter International and 3M.
- Bloomer compensation: $725,000 base salary, $150,000 sign-on bonus, 80% short-term incentive target, and a $3,300,000 long-term performance equity grant on joining.
- Fiscal 2027 equity: Bloomer is eligible for an additional $3,300,000 equity grant in November 2026, subject to Compensation and Leadership Development Committee approval.
- No disagreement: The filing states Sandercock's retirement did not result from any disagreement with the Company on operations, policies, or practices.
- Outlook reiterated: Alongside Q3 fiscal 2026 results, ResMed reiterated its fiscal 2026 outlook, including gross margin of 62-63% and an effective tax rate of 21-23%.
- Documentation: The company intends to file Bloomer's signed offer letter as an exhibit to its Form 10-Q for the quarter ended March 31, 2026.
03—Questions
Frequently Asked Questions
Why is ResMed's CFO leaving, and was it a dispute?
Brett Sandercock is retiring after 27 years with ResMed, including 20 as CFO. The filing states his decision did not result from any disagreement with the Company on any matter relating to its operations, policies, or practices.
Who is replacing the CFO and when does the change take effect?
Aaron Bloomer, previously Executive Vice President and CFO of Exact Sciences, is appointed CFO effective May 4, 2026, and will also serve as Principal Financial Officer and Principal Accounting Officer.
What is Sandercock's role after retiring?
He serves as Special Advisor to Chairman and CEO Mick Farrell through December 31, 2026, and continues as a consultant to Farrell from January 1, 2027 through December 31, 2027. He keeps vesting of outstanding equity awards under the ordinary terms of those grants and plans, and remains eligible for a six-month, pro-rata short-term incentive payment for fiscal year 2027.
What compensation does the new CFO receive?
Bloomer receives an annual base salary of $725,000, a $150,000 sign-on bonus (repayable if he voluntarily leaves within 24 months), an annual short-term incentive target of 80% of base salary pro-rated for fiscal year 2026, and a $3,300,000 long-term performance equity grant on joining. He is also eligible for another $3,300,000 equity grant in November 2026 for fiscal year 2027, subject to committee approval.
Did the company update its financial outlook with the leadership change?
The press release states ResMed reported third quarter fiscal year 2026 results the same day and reiterated its fiscal year 2026 outlook, including gross margin of 62-63%, SG&A expenses of 19-20%, R&D expenses of 6-7%, and an effective tax rate of 21-23%.
04—Continue